长汀县赢坪史前遗址发掘简报

2012年福建博物院对赢坪两处遗址进行了抢救性考古发掘,获得了一批包括石器、陶器、铜器、石范等内涵丰富的文化遗物,这批遗物可进一步了解闽西地区的史前文化发展序列及文化面貌,并且对于多地区文化间的交流研究也有一定的作用

120t复吹转炉底吹供气优化的模拟研究

针对天津钢铁集团有限公司120t复吹转炉,通过水力学物理模拟对转炉底吹供气进行了优化研究,寻求合理的底吹供气模式并进行生产实践。结果表明:转炉底吹对转炉熔池搅拌有很大的影响,喷嘴数目增加,熔池混匀时间有减小的趋势,与喷嘴流量均分模式相比,流量直线模式和"V"型模式混匀时间都得到改善,直线模式更有利于熔池的搅拌;优化后转炉冶炼有较大幅度的改善,转炉终点命中率提高,碳氧积更稳定,达到了强化转炉冶炼的目的

HIRFL-CSRe二极铁积分磁场测量

介绍了兰州重力加速器冷却储存环实验环二极磁铁积分长线圈测磁装置的构成,描述了实验环二极铁的分散性测量、横向分布测量、传递函数等测量内容及测量方法。实验环二极铁采用不断地加减硅钢铁片垫补和加调整线圈电流的方法来调整二极磁铁的有效长度来改变分散性。通过垫补和测量,二极磁铁的分散性在优化磁场时达到±2×10-4。同时给出了二极铁的横向分布和传递函数的测量结果。对二极铁的设计和加工进行了修正

End Optimization of Dipole Magnet of Super-FRS for FAIR

介绍了Super-FRS超导二极磁铁的磁场优化和端部削斜方案,采用OPERA软件对活极头进行削斜计算,得出合理的活极头尺寸,使各场下的积分均匀度在要求范围内达到了±2×10-4。最后将计算的积分场均匀度与磁场测量的结果进行比较,结果吻合得较好,验证了这种端部活极头优化计算方法的正确性。The end optimization of dipole magnet of Super-FRS for FAIR by OPERA-3D has been introduced in this paper.By using a complicated chamfer,the integral field homogeneity which is better than 2*10-4 can be obtained.In addition,the paper also introduced the comparison between the magnetic field measurement result and calculation one,which confirms the method of the removable pole end chamfer very well国家重点基础研究发展规划(973计划); 中国科学院近代物理研究所推进项

Determination of three kinds of chloroacetanilide herbicides in radix pseudostellariae by accelerated solvent extraction and gas chromatography-mass spectrometry

A gas chromatographic-mass spectrometry (CC-MS) method for the determination of herbicides acetochlor, butachlor and S-metolachlor in Radix Pseudostellariae (Taizishen in Chinese), a widely used Chinese medicinal herb, was developed. The herbicides in the plant. samples were extracted by accelerated solvent extraction (ASE). ASE conditions, including extraction solvent, temperature, clean-up reagent, flush volume, static time and static cycle were optimized. The extract was concentrated and then analyzed by GC-MS under select ion monitoring (SIM) mode. The herbicide residues were quantified by internal standard method. The detection limits and relative standard deviations for acetochlor, S-metolachlor and butachlor were 0.16 ng/g, 0.05 ng/g, 0.18 ng/g, and 2.6%, 3.1%, 3.9%, respectively. The average recoveries ranged from 80.2% to 104.1%. The three target herbicides were not detected in all the samples we analyzed. The method is easy to operation, and with good precision, it is therefore well suited for the routine analysis of herbicides. in herb samples such as Radix Pseudostellariae

Determination of Three Kinds of Chloroacetanilide Herbicides in Radix Pseudostellariae by Accelerated Solvent Extraction and Gas Chromatography-Mass Spectrometry

E-mail:[email protected][中文文摘]建立了太子参中乙草胺、丁草胺和S-异丙甲草胺的加速溶剂萃取-气相色谱/质谱测定的分析方法。对提取溶剂、萃取温度、净化材料、不同冲洗体积和静态萃取时间、循环次数等实验条件进行了优化。用HP-5MS弹性石英毛细管柱经柱程序升温技术分离,并用质谱检测器检测,内标法计算含量。本方法测定太子参中乙草胺、丁草胺和S-异丙甲草胺的检出限分别为0.16 ng/g、0.18 ng/g和0.05 ng/g,精密度分别为2.6%、3.9%和3.1%,回收率为80.2%-104.1%。所测样品不含上述3种除草剂残留。本方法简便、干扰小、检测效果好,可用于太子参药材中此类除草剂残留的分析。 [英文文摘] A gas chromatographic-mass spectrometry(GCMS) method for the determination of herbicides acetochlor,butachlor and S-metolachlor in Radix Pseudostellariae(Taizishen in Chinese),a widely used Chinese medicinal herb,was developed.The herbicides in the plant samples were extracted by accelerated solvent extraction(ASE).ASE conditions,including extraction solvent,temperature,clean-up reagent,flush volume,static time and static cycle were optimized.The extract was concentrated and then analyzed by GC-MS under select ion monitoring(SIM) mode.The herbicide residues were quantified by internal standard method.The detection limits and relative standard deviations for acetochlor,S-metolachlor and butachlor were 0.16 ng/g,0.05 ng/g,0.18 ng/g,and 2.6%,3.1%,3.9%,respectively.The average recoveries ranged from 80.2 % to 104.1 %.The three target herbicides were not detected in all the samples we analyzed.The method is easy to operation,and with good precision,it is therefore well suited for the routine analysis of herbicides in herb samples such as Radix Pseudostellariae.国家科技攻关计划基金资助项目(No.2003BA759C

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials